Biogen

News

Biogen bets $1.15bn on immunology drug developer HI-Bio

Biogen has expanded its specialty immunology pipeline with an agreement to buy Human Immunology Biosciences (HI-Bio) and its lead drug felzartamab, in trials for a range o

Market Access

NICE and the controversy over a ‘clinically distinct disease...

Payers worldwide are struggling with a new generation of precision medicines that come with a hefty price tag.

News

Eisai, Biogen start delayed subcutaneous Leqembi filing

Eisai and Biogen have filed a rolling biologics license application in the US for a subcutaneous formulation of Alzheimer’s disease therapy Leqembi that was delayed by the

News

Alzheimer’s drug Leqembi moves forward, still in low gear

Biogen has given an update on the rollout of its Eisai-partnered Alzheimer’s disease therapy Leqembi alongside its first-quarter results, showing that while the drug’s tak

News

Leqembi maintenance dose filed in US, but SC form delayed

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusio

Market Access